The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Strengthening multidisciplinary collaboration to enhance early-stage melanoma outcomes: A quality improvement initiative.
 
Vishal Patel
Leadership - Almirall Hermal GmbH; Biofrontera; Regeneron; Sun Pharma
Stock and Other Ownership Interests - Avstera; Science 37
Consulting or Advisory Role - Biofrontera; InflaRx; Regeneron; Sun Pharma
Speakers' Bureau - Regeneron
Research Funding - Regeneron
 
Muhammad Sarfraz Nawaz
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Lilly; Gilead Sciences; Janssen Oncology; Pharmacosmos; Pharmaessentia; Sanofi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Pharmacosmos
 
Ilona Dewald
No Relationships to Disclose
 
Samuel Dooyema
No Relationships to Disclose
 
Jeffrey Carter
No Relationships to Disclose
 
Cherilyn Heggen
No Relationships to Disclose
 
Kelly McKinnon
No Relationships to Disclose
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck